US Stock MarketDetailed Quotes
HUMA Humacyte
- 4.380
- -0.030-0.68%
Close Nov 21 16:00 ET
- 4.450
- +0.070+1.60%
Pre 08:15 ET
563.57MMarket Cap-3268P/E (TTM)
4.630High4.365Low2.97MVolume4.470Open4.410Pre Close13.25MTurnover3.16%Turnover RatioLossP/E (Static)128.67MShares9.97052wk High-8.85P/B412.22MFloat Cap2.43052wk Low--Dividend TTM94.11MShs Float17.450Historical High--Div YieldTTM6.01%Amplitude1.960Historical Low4.461Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Humacyte Stock Forum
Benzinga· 3 mins ago
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
what happened? the earnings suck but now the stock is rising
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Humacyte (HUMA) presented positive Phase 3 clinical trial results for their ATEV (acellular tissue engineered vessel) in arteriovenous access for hemodialysis patients. The trial demonstrated superior performance compared to standard autogenous fistula, with 81.3% functional patency at 6 months versus 66.4%, and 68.3% seco...
No comment yet